Personalized Proteomics to Understand and Predict Alzheimer’s Progression

This project studies blood proteins to understand why Alzheimer’s disease affects people differently, aiming to better predict its course and support more personalized treatment.

Alzheimer’s disease affects people differently, leading to varying rates of memory loss and cognitive decline. While blood tests can help detect early signs of Alzheimer’s, there’s still much to learn about why these differences occur. This project focuses on identifying new biomarkers to explain why individuals experience Alzheimer’s differently and predict who will be most affected. By discovering these markers, we aim to develop personalized tools for earlier intervention, improve predictions, and enhance the recruitment of participants for clinical trials.

What makes this project unique is its focus on understanding the biological differences in how Alzheimer’s disease affects people, using advanced proteomics. By finding early protein markers that reflect different patterns of cognitive decline across groups, the project aims to support more personalized and fair approaches to care.

This project will help uncover the biological reasons why changes in cognition differ from person to person among those at risk of Alzheimer’s disease. By identifying protein markers in the blood, we aim to develop a simple and accessible test to predict each individual’s risk of cognitive decline. This work will support earlier and more personalized care, improve how people are selected for clinical trials, and help speed up the discovery of targeted treatments, bringing us closer to precision medicine.